This study focuses on patients with primary lung tumors or secondary lung tumors who are scheduled to receive stereotactic body radiotherapy (SBRT). The study will use a radioactive imaging agent called [68Ga]Ga-MAA, which is a solution containing gallium and human albumin, given through an intravenous injection. This substance helps create detailed images of blood flow in the lungs using special scanning technology called PET/CT.
The purpose of this research is to compare two different approaches to planning radiation treatment. One approach uses functional lung imaging that shows blood flow patterns in the lungs, while the other uses traditional anatomical planning. The study aims to determine if using the blood flow imaging method results in fewer breathing problems or lung damage after radiation treatment.
During the study, participants will receive their prescribed radiation therapy and will have follow-up visits over one year to monitor their progress. The imaging agent will be used to create detailed pictures of their lungs before treatment and again three months after treatment. Doctors will check for any breathing difficulties or lung-related side effects throughout the study period. The maximum amount of the imaging agent used will be 200 MBq per scan, with a total of 400 MBq over two days.
France 
